JPH04266896A - Purification of alginic acid oligosaccharide and sulfuric acid group-containing oligosaccharide - Google Patents
Purification of alginic acid oligosaccharide and sulfuric acid group-containing oligosaccharideInfo
- Publication number
- JPH04266896A JPH04266896A JP2896891A JP2896891A JPH04266896A JP H04266896 A JPH04266896 A JP H04266896A JP 2896891 A JP2896891 A JP 2896891A JP 2896891 A JP2896891 A JP 2896891A JP H04266896 A JPH04266896 A JP H04266896A
- Authority
- JP
- Japan
- Prior art keywords
- oligosaccharide
- minutes
- alginic acid
- sodium chloride
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 61
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 38
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 38
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 33
- -1 alginic acid oligosaccharide Chemical class 0.000 title claims abstract description 28
- 239000000783 alginic acid Substances 0.000 title claims abstract description 20
- 229960001126 alginic acid Drugs 0.000 title claims abstract description 20
- 238000000746 purification Methods 0.000 title claims description 18
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 title abstract description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000010828 elution Methods 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000011780 sodium chloride Substances 0.000 claims abstract description 18
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 15
- 239000003957 anion exchange resin Substances 0.000 claims abstract description 14
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 9
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 8
- 239000005017 polysaccharide Substances 0.000 claims abstract description 8
- 150000004804 polysaccharides Chemical class 0.000 claims abstract description 8
- 229940072056 alginate Drugs 0.000 claims description 18
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 16
- 238000005194 fractionation Methods 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 2
- 239000011521 glass Substances 0.000 description 21
- 239000012153 distilled water Substances 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 7
- 125000001453 quaternary ammonium group Chemical group 0.000 description 7
- 241000512259 Ascophyllum nodosum Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 229940059329 chondroitin sulfate Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 3
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- MZDSOZBFTCRKNT-UHFFFAOYSA-N 3,6-dinitrophthalic acid Chemical compound OC(=O)C1=C(C(O)=O)C([N+]([O-])=O)=CC=C1[N+]([O-])=O MZDSOZBFTCRKNT-UHFFFAOYSA-N 0.000 description 2
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 2
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- OGLCQHRZUSEXNB-IXUMGEHXSA-N (3s,3ar,6s,6ar)-2,3,6-trihydroxy-3,3a,6,6a-tetrahydro-2h-furo[3,2-b]furan-5-one Chemical compound O[C@@H]1C(=O)O[C@@H]2[C@H](O)C(O)O[C@@H]21 OGLCQHRZUSEXNB-IXUMGEHXSA-N 0.000 description 1
- YKMMLFOYDTYAGR-UHFFFAOYSA-N 1-phenyl-2-(propan-2-ylamino)pentan-1-one Chemical compound CCCC(NC(C)C)C(=O)C1=CC=CC=C1 YKMMLFOYDTYAGR-UHFFFAOYSA-N 0.000 description 1
- 241000589563 Alteromonas sp. Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000002634 heparin fragment Substances 0.000 description 1
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004012 multidimensional HPLC Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012609 strong anion exchange resin Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012610 weak anion exchange resin Substances 0.000 description 1
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
【0001】0001
【産業上の利用分野】本発明は、高速液体クロマトグラ
フィー(以下、HPLCと略す)によるアルギン酸オリ
ゴ糖及び硫酸基含有オリゴ糖の精製法に関する[Field of Industrial Application] The present invention relates to a method for purifying alginate oligosaccharides and sulfate group-containing oligosaccharides by high performance liquid chromatography (hereinafter abbreviated as HPLC).
【000
2】000
2]
【従来の技術】その構造中に硫酸基やカルボキシル基等
を有する酸性多糖類としては、ヘパリン、ヘパラン硫酸
、コンドロイチン硫酸、アルギン酸などがあり、医薬品
や食品として従来より市販され利用されている。しかし
、これらの多糖の分解物であるオリゴ糖は、市販品はな
いか稀にあっても大変高価であり、またその利用法の研
究もあまり進んでいないのが現状である。ヘパリンの場
合、これまで抗凝血剤として広く使用されてきたが、ヘ
パリンを低分子化したヘパリン断片が、抗凝血剤〔 L
inhardt et al., (1982) J.
Biol. Chem. 257, 7310−73
13〕または抗腫瘍剤〔Folkman et al.
, (1983) Science 221,719−
725 〕としての効果を持つという報告もなされてい
る。BACKGROUND OF THE INVENTION Examples of acidic polysaccharides having sulfate groups, carboxyl groups, etc. in their structures include heparin, heparan sulfate, chondroitin sulfate, and alginic acid, which have been commercially available and used as pharmaceuticals and foods. However, oligosaccharides, which are decomposition products of these polysaccharides, are not commercially available, or even if they are rarely available, they are very expensive, and at present, research on how to use them has not made much progress. In the case of heparin, it has been widely used as an anticoagulant until now, but heparin fragments, which are lower molecular weight heparin, are used as anticoagulants [L
inhardt et al. , (1982) J.
Biol. Chem. 257, 7310-73
13] or antitumor agents [Folkman et al.
, (1983) Science 221, 719-
725] has also been reported to have the effect of
【0003】現在これらの多糖類のオリゴ糖の精製法と
しては、陰イオン交換樹脂を用いた多元高速液体クロマ
トグラフィー法〔Vella et al.,(198
9) J. Liquid Chromatograp
hy 12(8),1333−1346 〕) 、同じ
く陰イオン交換樹脂のオープンカラムによる方法〔コハ
ク酸含有オリゴ糖の精製法 TOYOPEARL NE
WS No.45 〕、電気透析と陰イオン交換樹脂オ
ープンカラムによる方法を組み合わせたもの〔シアル酸
含有オリゴ糖の精製法 特公昭63−28428〕、
酸性条件でのゲル濾過法〔アルギン酸加水分解物の精製
法Anzai et al.,(1990) Nipp
on Suisan Gakkaisi56(1),
73−81〕などが知られているが、これらゲル濾過法
やイオン交換法による精製法の場合、精製オリゴ糖を得
るまで二段階から数段階の精製過程を必要とし、工業的
規模での利用は困難であった。[0003]Currently, as a method for purifying oligosaccharides of these polysaccharides, a multidimensional high performance liquid chromatography method using an anion exchange resin [Vella et al. , (198
9) J. Liquid Chromatograph
hy 12(8), 1333-1346]), also a method using an open column of anion exchange resin [Method for purifying succinic acid-containing oligosaccharides TOYOPEARL NE
WS No. 45], a combination of electrodialysis and an anion exchange resin open column method [Purification method of sialic acid-containing oligosaccharides, Japanese Patent Publication No. 63-28428],
Gel filtration method under acidic conditions [purification method of alginic acid hydrolyzate Anzai et al. , (1990) Nipp.
on Suisan Gakkaisi56(1),
73-81], but these purification methods using gel filtration and ion exchange methods require two to several purification steps to obtain purified oligosaccharides, making it difficult to use them on an industrial scale. was difficult.
【0004】0004
【発明が解決しようとする課題】そこで、本発明者らは
、純度の高いアルギン酸オリゴ糖及び硫酸基含有オリゴ
糖を簡単にしかも迅速に調製する方法を開発すべく鋭意
研究を行い、アルギン酸オリゴ糖及び硫酸基含有オリゴ
糖が負の電荷を持っていることに着目し、陰イオン交換
樹脂とHPLCを組み合わせることにより上記開発目的
が達せられることを見出し本発明を完成するに至った。[Problems to be Solved by the Invention] Therefore, the present inventors conducted extensive research to develop a method for easily and quickly preparing highly pure alginate oligosaccharides and sulfate group-containing oligosaccharides. They focused on the fact that sulfate group-containing oligosaccharides have a negative charge, and found that the above development objective could be achieved by combining an anion exchange resin and HPLC, leading to the completion of the present invention.
【0005】[0005]
【課題を解決するための手段】すなわち、本発明はアル
ギン酸より調製したアルギン酸オリゴ糖を、陰イオン交
換樹脂カラムに吸着させ、高速液体クロマトグラフィー
にかけて、水と塩化ナトリウムで濃度勾配溶出し、分画
することを特徴とするアルギン酸オリゴ糖の精製法であ
る。[Means for Solving the Problems] That is, the present invention adsorbs alginic acid oligosaccharide prepared from alginic acid onto an anion exchange resin column, subjects it to high performance liquid chromatography, performs concentration gradient elution with water and sodium chloride, and fractionates it. This is a method for purifying alginate oligosaccharides.
【0006】さらに、本発明はその構造中に硫酸基を含
む多糖より調製した硫酸基含有オリゴ糖を、陰イオン交
換樹脂カラムに吸着させ、高速液体クロマトグラフィー
にかけて、水と塩化ナトリウムで濃度勾配溶出し、分画
することを特徴とする硫酸基含有オリゴ糖の精製法であ
る。上記精製法において、水と塩化ナトリウムによる濃
度勾配溶出は、塩化ナトリウムの濃度を0から0.25
M まで40分間で直線的に上昇させたのち、2Mに5
分間保ち、次に15分間水だけを流すことにより行なわ
れる。Furthermore, the present invention involves adsorbing a sulfate group-containing oligosaccharide prepared from a polysaccharide containing a sulfate group in its structure onto an anion exchange resin column, subjecting it to high performance liquid chromatography, and eluting with a concentration gradient using water and sodium chloride. This is a method for purifying sulfate group-containing oligosaccharides, which is characterized by fractionating the oligosaccharides. In the above purification method, concentration gradient elution with water and sodium chloride increases the concentration of sodium chloride from 0 to 0.25.
After increasing linearly to M in 40 minutes, increasing to 2M by 5
This is done by holding for 15 minutes and then flushing only water for 15 minutes.
【0007】本発明で使用されるHPLC用陰イオン交
換樹脂カラムとしては市販のものが用いられるが、その
例としてはProtein Pak G−DEAE (
Waters製)、Protein Pak G−QA
(Waters製)、COSMOGEL DEAE
GLASS (ナカライテスク製)、COSMOGEL
QA GLASS (ナカライテスク製)、Mono
Q (Pharmacia 製)、TSKgel D
EAE (東ソ−製)、TSKgel QAE(東ソ−
製)などが挙げられる。[0007] As the anion exchange resin column for HPLC used in the present invention, a commercially available one can be used, and an example thereof is Protein Pak G-DEAE (
Waters), Protein Pak G-QA
(manufactured by Waters), COSMOGEL DEAE
GLASS (manufactured by Nacalai Tesque), COSMOGEL
QA GLASS (manufactured by Nacalai Tesque), Mono
Q (manufactured by Pharmacia), TSKgel D
EAE (manufactured by Tosoh), TSKgel QAE (manufactured by Tosoh)
(manufactured by).
【0008】本発明の精製法に供されるアルギン酸オリ
ゴ糖を含む原料としては、アルギン酸ナトリウムやアル
ギン酸カリウムをアルギン酸リアーゼで分解した物、褐
藻など(例えばワカメ、コンブ、ヒジキなど)のアルギ
ン酸を細胞内に含む物をアルギン酸リアーゼで分解した
物、またはこれらアルギン酸を含む物を硫酸などの酸で
加水分解した物が用いられる。硫酸基含有オリゴ糖のを
含む原料としては、ヘパリンをヘパリナーゼで分解した
物、ヘパラン硫酸をヘパリチナーゼで分解した物、コン
ドロイチン硫酸をコンドロイチナーゼで分解した物など
が用いられる。Raw materials containing alginate oligosaccharides to be subjected to the purification method of the present invention include sodium alginate and potassium alginate decomposed with alginate lyase, and alginic acid from brown algae (for example, wakame, kelp, hijiki, etc.) A product obtained by decomposing a substance containing alginic acid with alginic acid lyase, or a product obtained by hydrolyzing a substance containing alginic acid with an acid such as sulfuric acid is used. As raw materials containing sulfate group-containing oligosaccharides, heparin decomposed with heparinase, heparan sulfate decomposed with heparitinase, chondroitin sulfate decomposed with chondroitinase, etc. are used.
【0009】次に、本発明の精製法の操作手順について
説明する。まず、HPLCに陰イオン交換樹脂を充填し
たカラムをつなぎ、溶媒には水を用いて平衡化する。そ
のカラムに遠心分離または濾過により不溶物を除去した
アルギン酸オリゴ糖もしくは硫酸基含有オリゴ糖溶液を
注入し、樹脂に吸着させる。このとき、試料の脱色操作
は必要としない。次に塩化ナトリウムの濃度を0から0
.25Mまで40分間で直線的に上昇させたのち、2M
に5分間保ち、次に15分間水だけを流す。フラクショ
ンコレクターを用いて分画し、オリゴ糖の各画分を回収
することで、アルギン酸オリゴ糖もしくは硫酸基含有オ
リゴ糖の精製は終了する。この一連の操作は、60分を
1単位として、注入と溶出を繰り返し行うことができる
。この後、必要に応じて脱塩と濃縮を行う。Next, the operating procedure of the purification method of the present invention will be explained. First, a column filled with an anion exchange resin is connected to HPLC, and water is used as a solvent for equilibration. An alginic acid oligosaccharide or sulfate group-containing oligosaccharide solution from which insoluble matter has been removed by centrifugation or filtration is injected into the column and adsorbed onto the resin. At this time, there is no need to decolorize the sample. Next, increase the concentration of sodium chloride from 0 to 0.
.. After ascending linearly to 25M in 40 minutes, 2M
5 minutes, then run only water for 15 minutes. Purification of the alginic acid oligosaccharide or the sulfate group-containing oligosaccharide is completed by fractionating the oligosaccharide using a fraction collector and collecting each fraction of the oligosaccharide. In this series of operations, injection and elution can be repeated in units of 60 minutes. After this, desalting and concentration are performed as necessary.
【0010】0010
【実施例】以下、本発明を実施例により具体的に説明す
る。但し、本発明の技術的範囲がこれらの実施例により
限定されるものではない。[Examples] The present invention will be specifically explained below using examples. However, the technical scope of the present invention is not limited to these Examples.
【0011】[0011]
【実施例1】アルギン酸ナトリウム (和光純薬製)
をAlteromonas sp. 微工研菌寄第11
685 号 (特願平2−294897号) 由来のア
ルギン酸リアーゼにより分解した分解物 (以下アルギ
ン酸オリゴ糖と言う) のDEAE分析用カラムによる
精製法
HPLC (LC−7Aシリーズ、島津製作所製) に
、ジエチルアミノエチル(DEAE)型弱陰イオン交換
樹脂の分析用カラムであるDEAE GLASS (
ナカライテスク製、8mm×75mm、10μm )
とDEAE GLASSガードカラム(ナカライテス
ク製、8mm×10mm、30μm ) とをつなぎ、
これを蒸留水で平衡化した。このカラムに10%(w/
v) アルギン酸オリゴ糖溶液を10000r.p.m
. で10分間遠心分離した上清を2μl 注入した。
次に、蒸留水と2M塩化ナトリウム水溶液を用いて、塩
化ナトリウムの濃度を40分間で0〜0.25Mまで直
線的に上昇させた後、即塩化ナトリウム濃度を2Mに上
げ5分間その濃度に保ち、その後蒸留水を15分間流し
て溶出した。この間 230nmでの吸収を測定する
(リアーゼは脱離反応によって、分解物に二重結合を作
るため、二重結合の最大吸収波長である 230nmを
用いた。) ことによって溶出状態をモニターしたとこ
ろ、溶出時間15.465分から31.005分まで8
個のピークが観察された (図1参照) 。同時にフラ
クションコレクターでピークモードを用いてピークごと
に分画したところ、15.465分と16.942分、
19.742分、21.942分と23.275分、2
5.369分、27.977分、31.005分の6個
に分画された。これら6個の画分について、3,6−ジ
ニトロフタル酸法を用いて還元糖量を測定した結果、
230nmでの吸収により観察されたピークは、糖のピ
ークであることがわかった (図2参照) 。流量は0
.6 ml/minで行った。[Example 1] Sodium alginate (manufactured by Wako Pure Chemical Industries)
Alteromonas sp. Microtechnology Research Institute No. 11
No. 685 (Patent Application No. 2-294897) A purification method using a column for DEAE analysis of a decomposed product (hereinafter referred to as alginate oligosaccharide) decomposed by alginate lyase derived from DEAE GLASS is an analytical column using ethyl (DEAE) type weak anion exchange resin.
Made by Nacalai Tesque, 8mm x 75mm, 10μm)
and a DEAE GLASS guard column (manufactured by Nacalai Tesque, 8 mm x 10 mm, 30 μm).
This was equilibrated with distilled water. 10% (w/
v) Add the alginate oligosaccharide solution to 10,000 rpm. p. m
.. 2 μl of the supernatant obtained by centrifugation for 10 minutes was injected. Next, using distilled water and a 2M sodium chloride aqueous solution, the concentration of sodium chloride was linearly increased from 0 to 0.25M in 40 minutes, and then the sodium chloride concentration was immediately raised to 2M and kept at that concentration for 5 minutes. , and then eluted by running distilled water for 15 minutes. During this time, measure the absorption at 230 nm.
(Since lyase creates double bonds in decomposed products through an elimination reaction, we used 230 nm, which is the maximum absorption wavelength of double bonds.) When the elution state was monitored by this method, the elution time was 15.465 minutes. 8 until 005 minutes
Several peaks were observed (see Figure 1). At the same time, when we fractionated each peak using peak mode with a fraction collector, the results were 15.465 minutes and 16.942 minutes.
19.742 minutes, 21.942 minutes and 23.275 minutes, 2
It was fractionated into six fractions: 5.369 minutes, 27.977 minutes, and 31.005 minutes. As a result of measuring the amount of reducing sugar in these six fractions using the 3,6-dinitrophthalic acid method,
The peak observed by absorption at 230 nm was found to be a sugar peak (see Figure 2). Flow rate is 0
.. The flow rate was 6 ml/min.
【0012】0012
【実施例2】アルギン酸オリゴ糖のQA分析用カラムに
よる精製法。
第4級アンモニウム(QA)型強陰イオン交換樹脂の分
析用カラムQA GLASS (ナカライテスク製、8
mm×75mm、10μm ) とQA GLASS
ガードカラム (ナカライテスク製、8mm×10mm
、30μm ) とを実施例1の場合と同様に平衡化し
、アルギン酸オリゴ糖上清2μl を注入して吸着させ
た。実施例1と同様に蒸留水と2M塩化ナトリウム水溶
液の濃度勾配を用いて溶出した。 230nmでの吸収
で溶出状態をモニターしたところ、溶出時間28.50
7分から43.792分まで8個の画分に分画精製でき
たが、DEAEに比べてカラム保持時間が長くなった
(図3参照) 。[Example 2] Purification method of alginate oligosaccharide using a QA analysis column. Quaternary ammonium (QA) type strong anion exchange resin analytical column QA GLASS (manufactured by Nacalai Tesque, 8
mm x 75mm, 10μm) and QA GLASS
Guard column (manufactured by Nacalai Tesque, 8mm x 10mm
, 30 μm) were equilibrated in the same manner as in Example 1, and 2 μl of alginate oligosaccharide supernatant was injected for adsorption. Elution was carried out in the same manner as in Example 1 using a concentration gradient of distilled water and a 2M aqueous sodium chloride solution. When the elution state was monitored by absorption at 230 nm, the elution time was 28.50.
Although it was possible to fractionate and purify 8 fractions from 7 minutes to 43.792 minutes, the column retention time was longer than that of DEAE.
(See Figure 3).
【0013】[0013]
【実施例3】アルギン酸オリゴ糖の分取用カラムによる
精製法
HPLC (ALC/GPC 609G、Water
s製) に分取用DEAE GLASS (ナカライ
テスク製、20mm×100mm 、30μm ) と
DEAE GLASSガードカラムとをつなぎ、蒸留
水で平衡化した。実施例1と同様にアルギン酸オリゴ糖
上清を 200μl 注入した。流量は5ml/min
で行い、実施例1と同様に溶出した。230nm の吸
収により溶出状態をモニターしたところ、分析用カラム
の場合と同様に、 20.84分、 22.39分、
26.43分、 28.50分、 29.56分、31
.51分、 33.27分、 35.24分の8個のピ
ークが観察され、フラクションコレクターを用いて各ピ
ークごとに8個に分画して回収した (図4参照) 。
そして、フェノール・硫酸法により、D−マンノフラヌ
ロノ−6、3−ラクトンを標準として全糖量を算出した
結果、8個の画分の収量は、それぞれ0.9mg 、4
.5mg 、6.2mg 、1.8mg 、4.4mg
、2.0mg 、1.8mg 、4.6mg であっ
た。[Example 3] Purification method of alginate oligosaccharide using a preparative column HPLC (ALC/GPC 609G, Water
A preparative DEAE GLASS (manufactured by Nacalai Tesque, 20 mm x 100 mm, 30 μm) and a DEAE GLASS guard column were connected to a DEAE GLASS (manufactured by Nacalai Tesque) and equilibrated with distilled water. In the same manner as in Example 1, 200 μl of alginate oligosaccharide supernatant was injected. Flow rate is 5ml/min
The elution was carried out in the same manner as in Example 1. When the elution state was monitored by absorption at 230 nm, the results were as follows: 20.84 minutes, 22.39 minutes,
26.43 minutes, 28.50 minutes, 29.56 minutes, 31
.. Eight peaks at 51 minutes, 33.27 minutes, and 35.24 minutes were observed, and each peak was fractionated into 8 peaks and collected using a fraction collector (see Figure 4). Then, as a result of calculating the total sugar content using D-mannofuranurono-6,3-lactone as a standard using the phenol/sulfuric acid method, the yields of the 8 fractions were 0.9 mg and 4 mg, respectively.
.. 5mg, 6.2mg, 1.8mg, 4.4mg
, 2.0 mg, 1.8 mg, and 4.6 mg.
【0014】[0014]
【実施例4】アルギン酸を主成分に持つ代表的なもので
あるコンブの粉末(ミツイシコンブ粉末) をアルギン
酸リアーゼで分解した分解物 (以下コンブオリゴ糖と
呼ぶ) の分析用カラムによる精製法
実施例1と同様にHPLCに分析用DEAE GLA
SSカラムとDEAE GLASSガードカラムとを
つなぎ、蒸留水で平衡化した。10%(w/v) コン
ブオリゴ糖溶液を10000r.p.m. で10分間
遠心した上清を10μl 注入した。流量は0.6ml
/minで、実施例1と同様に溶出分画した。アルギン
酸オリゴ糖の場合と同様に、溶出時間27.522分か
ら44.544分まで8個に分画精製できた (図5参
照) 。[Example 4] Purification method using an analytical column for a decomposition product (hereinafter referred to as kelp oligosaccharide) obtained by decomposing kelp powder (Kombu kelp powder), which is a typical product containing alginic acid as a main component, using alginate lyase. Similarly, DEAE GLA for HPLC analysis
The SS column and DEAE GLASS guard column were connected and equilibrated with distilled water. A 10% (w/v) kelp oligosaccharide solution was added at 10,000 rpm. p. m. 10 μl of the supernatant obtained by centrifugation for 10 minutes was injected. Flow rate is 0.6ml
/min, and elution and fractionation were performed in the same manner as in Example 1. As in the case of alginate oligosaccharides, fractionation and purification into eight components was possible from elution time of 27.522 minutes to 44.544 minutes (see Figure 5).
【0015】[0015]
【実施例5】硫酸基含有多糖であるコンドロイチン硫酸
C (生化学工業製) をコンドロイチナーゼABC
(生化学工業製) で分解した分解物 (以下ChS−
Cオリゴ糖と呼ぶ) の分析用カラムによる精製法実施
例1と同様に、分析用DEAE GLASSカラムと
DEAEGLASSガードカラムとをつなぎ、蒸留水で
平衡化した。10mg/mlChS−Cオリゴ糖液を5
0μl 注入した。流量は0.6ml/minで、実施
例1と同様に溶出した。その結果、31.114分(図
6参照) に、コンドロイチン硫酸Cのコンドロイチナ
ーゼABCによる最終分解産物である二糖の画分を得た
。[Example 5] Chondroitin sulfate C (manufactured by Seikagaku Corporation), a sulfate group-containing polysaccharide, was converted into chondroitinase ABC.
(manufactured by Seikagaku Corporation) (hereinafter referred to as ChS-
Purification method using an analytical column for (referred to as C oligosaccharide) As in Example 1, an analytical DEAE GLASS column and a DEAE GLASS guard column were connected and equilibrated with distilled water. 10mg/ml ChS-C oligosaccharide solution
0 μl was injected. The flow rate was 0.6 ml/min, and elution was carried out in the same manner as in Example 1. As a result, a disaccharide fraction, which is the final degradation product of chondroitin sulfate C by chondroitinase ABC, was obtained at 31.114 minutes (see FIG. 6).
【0016】[0016]
【実施例6】硫酸基含有多糖であるコンドロイチン硫酸
A (ナカライテスク製) をコンドロイチナーゼAB
Cで分解した分解物 (以下ChS−Aオリゴ糖と呼ぶ
) の分析用カラムによる精製法
実施例1と同様に、分析用DEAE GLASSカラ
ムとDEAEGLASSガードカラムをつなぎ、蒸留水
で平衡化した。25mg/ml ChS−Aオリゴ糖溶
液を50μl 注入した。その結果、28.718分
(図7参照) に、コンドロイチン硫酸Aのコンドロイ
チナーゼABCによる最終分解産物である二糖の画分を
得た。[Example 6] Chondroitin sulfate A (manufactured by Nacalai Tesque), a sulfate group-containing polysaccharide, was added to chondroitinase AB.
Purification method using an analytical column for a decomposed product (hereinafter referred to as ChS-A oligosaccharide) decomposed with C As in Example 1, an analytical DEAE GLASS column and a DEAE GLASS guard column were connected and equilibrated with distilled water. 50 μl of 25 mg/ml ChS-A oligosaccharide solution was injected. As a result, 28.718 minutes
(See Figure 7) A disaccharide fraction, which is the final degradation product of chondroitin sulfate A by chondroitinase ABC, was obtained.
【0017】[0017]
【実施例7】アルギン酸オリゴ糖の異なる濃度匂配での
クロマトグラフィーを示す。実施例1と同様にHPLC
に分析用DEAE GLASSとDEAE GLA
SSガードカラムをつなぎ平衡化させた。アルギン酸オ
リゴ糖上清2μlを注入して吸着させた。最初の5分間
は蒸留水だけを流し、次に20分間で塩化ナトリウムの
濃度を0から0.5Mまで上昇させた後、すぐに蒸留水
だけを流した。本発明の濃度匂配を用いた場合に比べて
、溶出にかかる時間は半分(30分)となったが、分離
が悪くなった。(図8参照)Example 7 shows the chromatography of alginate oligosaccharides at different concentration profiles. HPLC as in Example 1
DEAE GLASS and DEAE GLA for analysis
The SS guard column was connected and equilibrated. 2 μl of alginate oligosaccharide supernatant was injected and adsorbed. Only distilled water was allowed to flow for the first 5 minutes, then the concentration of sodium chloride was increased from 0 to 0.5M over 20 minutes, and then only distilled water was allowed to flow immediately. The time required for elution was halved (30 minutes) compared to when the concentration ratio of the present invention was used, but the separation was worse. (See Figure 8)
【0018】[0018]
【実施例8】C18カラムであるNOVA PAK C
18 (4μSpherical 、3.9 ×150
、Waters製)でクロマトグラフィーを示す。H
PLCにNOVA PAK C18をつなぎ、アセトニ
トリル:蒸留水(80:20)混合液で平衡化させ、ア
ルギン酸オリゴ糖上清5μlを注入し、同混合液で溶出
した。
流量は1ml/minを用いた。(図9参照)アセトニ
トリルと蒸留水の割合や流量をいろいろに変化させてみ
たが、上記条件でのもの(図9参照)の分離が一番良く
、これ以上改善できなかった。[Example 8] NOVA PAK C which is a C18 column
18 (4μSpherical, 3.9 × 150
, Waters). H
NOVA PAK C18 was connected to a PLC, equilibrated with acetonitrile:distilled water (80:20) mixture, 5 μl of alginate oligosaccharide supernatant was injected, and elution was performed with the same mixture. A flow rate of 1 ml/min was used. (See Figure 9) We tried varying the ratio and flow rate of acetonitrile and distilled water, but the separation under the above conditions (see Figure 9) was the best and no further improvement could be made.
【0019】[0019]
【発明の効果】本発明はHPLCと陰イオン交換樹脂カ
ラムの使用により、これらのオリゴ糖を極めて容易に分
画することができた。すなわち、本発明は一回のクロマ
トグラフィーで精製でき、しかも、精製で用いる溶媒は
、蒸留水と塩化ナトリウムだけであるため、この後に脱
塩を行う場合においても極めて容易である。また、本発
明の場合、カラムの洗浄も含めて、60分を一単位とし
て一回のクロマトグラフィーを組み立てているため、オ
ートインジェクターとフラクションコレクターを併用す
れば、自動化が可能である。また、陰イオン交換樹脂カ
ラムは、他のHPLC用カラム (例えば、ODSカラ
ム、ゲル濾過カラム、NH2 カラムなど) に比べて
、取扱いが簡単で、再現性が良く、耐久性も高いため、
工業的規模の大量調製への移行も容易である。Effects of the Invention The present invention was able to very easily fractionate these oligosaccharides by using HPLC and an anion exchange resin column. That is, in the present invention, the product can be purified by a single chromatography, and since the only solvents used for the purification are distilled water and sodium chloride, it is extremely easy to desalt afterward. Furthermore, in the case of the present invention, one chromatography is assembled in 60 minutes, including column washing, so automation is possible by using an autoinjector and a fraction collector together. Additionally, anion exchange resin columns are easier to handle, have better reproducibility, and are more durable than other HPLC columns (e.g., ODS columns, gel filtration columns, NH2 columns, etc.).
It is also easy to transfer to large-scale preparation on an industrial scale.
【図1】実施例1の分析用DEAE GLASSでの
アルギン酸オリゴ糖の溶出結果を示す図。FIG. 1 is a diagram showing the elution results of alginic acid oligosaccharides using DEAE GLASS for analysis in Example 1.
【図2】実施例1の各画分の還元糖量を3,6−ジニト
ロフタル酸法で測定した結果を示す図。縦軸はグルコー
スを標準として算出した各画分中の還元糖量を示し、横
軸は各画分を溶出順に示す。FIG. 2 is a diagram showing the results of measuring the amount of reducing sugar in each fraction of Example 1 using the 3,6-dinitrophthalic acid method. The vertical axis shows the amount of reducing sugar in each fraction calculated using glucose as a standard, and the horizontal axis shows each fraction in the order of elution.
【図3】実施例2の分析用QA GLASSでのアル
ギン酸オリゴ糖の溶出結果を示す図。FIG. 3 is a diagram showing the elution results of alginate oligosaccharide using analytical QA GLASS in Example 2.
【図4】実施例3の分取用DEAE GLASSでの
アルギン酸オリゴ糖の溶出結果を示す図。FIG. 4 is a diagram showing the elution results of alginate oligosaccharides in preparative DEAE GLASS in Example 3.
【図5】実施例4の分析用DEAE GLASSでの
コンブオリゴ糖の溶出結果を示す図。FIG. 5 is a diagram showing the elution results of kelp oligosaccharide in DEAE GLASS for analysis in Example 4.
【図6】実施例5の分析用DEAE GLASSでの
ChS−Cオリゴ糖の溶出結果を示す図。FIG. 6 is a diagram showing the elution results of ChS-C oligosaccharides in DEAE GLASS for analysis in Example 5.
【図7】実施例6の分析用DEAE GLASSでの
ChS−Aオリゴ糖の溶出結果を示す図。FIG. 7 is a diagram showing the elution results of ChS-A oligosaccharides in DEAE GLASS for analysis in Example 6.
【図8】実施例7の異なる濃度匂配でのアルギン酸オリ
ゴ糖の溶出曲線を示す図。FIG. 8 is a diagram showing the elution curves of alginate oligosaccharides at different concentrations in Example 7.
【図9】実施例8のアセトニトリルと蒸留水で溶出した
結果を示す図。FIG. 9 is a diagram showing the results of elution with acetonitrile and distilled water in Example 8.
Claims (4)
リゴ糖を、陰イオン交換樹脂カラムに吸着させ高速液体
クロマトグラフィーにかけて、水と塩化ナトリウムで濃
度勾配溶出し分画することを特徴とするアルギン酸オリ
ゴ糖の精製法。Claim 1: Purification of alginic acid oligosaccharides, which is characterized by adsorbing alginic acid oligosaccharides prepared from alginic acid onto an anion exchange resin column and subjecting them to high performance liquid chromatography, followed by concentration gradient elution and fractionation with water and sodium chloride. Law.
を、塩化ナトリウムの濃度を0から0.25M まで4
0分間で直線的に上昇させたのち、2Mに5分間保ち、
次に15分間水だけを流すことにより行うことを特徴と
する請求項1記載のアルギン酸オリゴ糖の精製法。Claim 2: Perform concentration gradient elution with water and sodium chloride, increasing the concentration of sodium chloride from 0 to 0.25M.
After raising it linearly for 0 minutes, keep it at 2M for 5 minutes,
2. The method for purifying alginate oligosaccharide according to claim 1, which is then carried out by flowing only water for 15 minutes.
製した硫酸基含有オリゴ糖を、陰イオン交換樹脂カラム
に吸着させ高速液体クロマトグラフィーにかけて、水と
塩化ナトリウムで濃度勾配溶出し分画することを特徴と
する硫酸基含有オリゴ糖の精製法。Claim 3: A sulfate group-containing oligosaccharide prepared from a polysaccharide containing a sulfate group in its structure is adsorbed onto an anion exchange resin column, subjected to high performance liquid chromatography, and fractionated by concentration gradient elution with water and sodium chloride. A method for purifying sulfate group-containing oligosaccharides.
を、塩化ナトリウムの濃度を0から0.25M まで4
0分間で直線的に上昇させたのち、2Mに5分間保ち、
次に15分間水だけを流すことにより行うことを特徴と
する請求項3記載の硫酸基含有オリゴ糖の精製法。Claim 4: Concentration gradient elution with water and sodium chloride is performed with the concentration of sodium chloride ranging from 0 to 0.25M.
After raising it linearly for 0 minutes, keep it at 2M for 5 minutes,
4. The method for purifying a sulfate group-containing oligosaccharide according to claim 3, which is then carried out by flowing only water for 15 minutes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2896891A JPH04266896A (en) | 1991-02-22 | 1991-02-22 | Purification of alginic acid oligosaccharide and sulfuric acid group-containing oligosaccharide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2896891A JPH04266896A (en) | 1991-02-22 | 1991-02-22 | Purification of alginic acid oligosaccharide and sulfuric acid group-containing oligosaccharide |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH04266896A true JPH04266896A (en) | 1992-09-22 |
Family
ID=12263216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2896891A Pending JPH04266896A (en) | 1991-02-22 | 1991-02-22 | Purification of alginic acid oligosaccharide and sulfuric acid group-containing oligosaccharide |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH04266896A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1059679C (en) * | 1993-06-18 | 2000-12-20 | 青岛海洋大学 | Sodium alginate diester and preparation method |
JP2012082436A (en) * | 2004-08-12 | 2012-04-26 | Lipoxen Technologies Ltd | Fractionation of charged polysaccharide |
-
1991
- 1991-02-22 JP JP2896891A patent/JPH04266896A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1059679C (en) * | 1993-06-18 | 2000-12-20 | 青岛海洋大学 | Sodium alginate diester and preparation method |
JP2012082436A (en) * | 2004-08-12 | 2012-04-26 | Lipoxen Technologies Ltd | Fractionation of charged polysaccharide |
JP2014169451A (en) * | 2004-08-12 | 2014-09-18 | Lipoxen Technologies Ltd | Fractionation of charged polysaccharide |
US9200052B2 (en) | 2004-08-12 | 2015-12-01 | Lipoxen Technologies Limited | Fractionation of charged polysaccharide |
US9790288B2 (en) | 2004-08-12 | 2017-10-17 | Lipoxen Technologies Limited | Fractionation of charged polysaccharide |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hook et al. | Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin | |
EP0027089B1 (en) | Oligosaccharide fractions and oligosaccharides with biological properties, process for their preparation and their uses as medicines | |
EP0046581B1 (en) | Process for separation of mucopolysaccharides | |
Ringertz et al. | Chromatography on ECTEOLA of sulfate containing mucopolysaccharides | |
Flodin et al. | Separation of acidic oligosaccharides by gel filtration | |
Galeotti et al. | Novel reverse-phase ion pair-high performance liquid chromatography separation of heparin, heparan sulfate and low molecular weight-heparins disaccharides and oligosaccharides | |
CN104610467B (en) | Method for separating hyaluronate tetrasaccharide from hyaluronate hexasaccharide | |
Damm et al. | Separation of natural and synthetic heparin fragments by high-performance capillary electrophoresis | |
US4486420A (en) | Mucopolysaccharide composition having a regulatory action on coagulation, medicament process for preparation and method of use | |
Volpi | Disaccharide mapping of chondroitin sulfate of different origins by high-performance capillary electrophoresis and high-performance liquid chromatography | |
Sutton et al. | Chiral capillary electrophoresis with noncyclic oligo‐and polysaccharide chiral selectors | |
EP2697265B1 (en) | Polysaccharides comprising two antithrombin iii-binding sites, preparation thereof and use thereof as antithrombotic medicaments | |
Patel et al. | Effective reversed-phase ion pair high-performance liquid chromatography method for the separation and characterization of intact low-molecular-weight heparins | |
Murata et al. | Chondroitin sulfate isomers in normal human urine | |
JPH04266896A (en) | Purification of alginic acid oligosaccharide and sulfuric acid group-containing oligosaccharide | |
Nagasawa et al. | Chemical change involved in the oxidative-reductive depolymerization of heparin | |
CN110592165B (en) | Extraction method and structure analysis of heparan sulfate/heparin in cubilose | |
Gonçalves et al. | Positional isomers of sulfated oligosaccharides obtained from agarans and carrageenans: preparation and capillary electrophoresis separation | |
Larnkjaer et al. | Isolation and charaterization of hexasaccharides derived from heparin. Analysis by HPLC and elucidation of structure by 1H NMR | |
JPS59149901A (en) | Heparin purification and fractionation | |
US3753972A (en) | Fractionation of agar | |
Kosakai et al. | Isolation and characterization of sulfated disaccharides from the deamination products of porcine heparin (α-Heparin) and whale heparin (ω-Heparin), and a comparison of the deamination products | |
RU2006123543A (en) | METHOD FOR CLEANING BETA INTERFERON | |
Vijayabaskar et al. | Low-molecular weight molluscan glycosaminoglycan from bivalve Katelysia opima (Gmelin) | |
CN105399870B (en) | A kind of low-anticoagulant heparin, its oligosaccharide and preparation method thereof and the application in the medicine for preparing anti-alzheimer's disease |